Thus, the selective P2X3, P2X2/3 receptor antagonist A-317491 transiently attenuates cancer-induced bone pain in mice, but has no effect at the late stage of bone cancer (Hansen et al., 2012). Here, P2RX3 is linked to bone neoplasm.